Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice
Tomimatsu, Nozomi, Mukherjee, Bipasha, Catherine Hardebeck, Molly, Ilcheva, Mariya, Vanessa Camacho, Cristel, Louise Harris, Janelle, Porteus, Matthew, Llorente, Bertrand, Khanna, Kum Kum, Burma, Sandeep
Published in Nature communications (07.04.2014)
Published in Nature communications (07.04.2014)
Get full text
Journal Article
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
GIL DEL ALCAZAR, Carlos Rodrigo, HARDEBECK, Molly Catherine, BURMA, Sandeep, MUKHERJEE, Bipasha, TOMIMATSU, Nozomi, XIAOHUAN GAO, JINGSHENG YAN, XIE, Xian-Jin, BACHOO, Robert, LI LI, HABIB, Amyn A
Published in Clinical cancer research (01.03.2014)
Published in Clinical cancer research (01.03.2014)
Get full text
Journal Article
DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair
Tomimatsu, Nozomi, Mukherjee, Bipasha, Harris, Janelle Louise, Boffo, Francesca Ludovica, Hardebeck, Molly Catherine, Potts, Patrick Ryan, Khanna, Kum Kum, Burma, Sandeep
Published in The Journal of biological chemistry (30.06.2017)
Published in The Journal of biological chemistry (30.06.2017)
Get full text
Journal Article
Abstract P1-19-09: Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3)
O’Shaughnessy, Joyce, Johnston, Stephen, Martin, Miguel, Huober, Jens, Toi, Masakazu, Andre, Valerie AnneMarie, Martin, Holly Rene, Hardebeck, Molly Catherine, Di Leo, Angelo, Goetz, Matthew Philip
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article
A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease
Yee, Douglas, LoRusso, Patricia, Sablin, Marie Paule, Prat, Aleix, Stradella, Agostina, Utriainen, Meri, Oliveira, Mafalda, Yonemori, Kan, Naito, Yoichi, Hardebeck, Molly Catherine, Puig, Marta, Hu, Joy, Biyukov, Tsvetan Nikolov, Iwata, Hiroji
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort
LoRusso, Patricia, García-Corbacho, Javier, Braiteh, Fadi S., Gonçalves, Anthony, Ricci, Francesco, Iwata, Hiroji, Capelán, Marta, Sablin, Marie Paule, Prat, Aleix, Hardebeck, Molly Catherine, Puig, Marta, Huang, Dennis Chin-Lun, Hsu, Mingchi, Yee, Douglas
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
Abstract P3-11-05: A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts
Yee, Douglas, Oliveira, Mafalda, Iwata, Hiroji, Gonçalves, Anthony, García-Corbacho, Javier, Sablin, Marie Paule, Prat, Aleix, Hardebeck, Molly Catherine, Puig, Marta, Huang, Dennis Chin-Lun, Hsu, Mingchi, LoRusso, Patricia
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article